Comparative Pharmacology
Head-to-head clinical analysis: PLENVU versus SUTAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PLENVU versus SUTAB.
PLENVU vs SUTAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PLENVU is an osmotic laxative that induces bowel cleansing by causing water retention in the colon, leading to increased intraluminal pressure and stimulation of peristalsis. Its components (polyethylene glycol 3350, sodium ascorbate, ascorbic acid, sodium sulfate) act synergistically to produce a cathartic effect.
SUTAB is a combination tablet consisting of sodium sulfate, magnesium sulfate, and potassium chloride. It acts as an osmotic laxative by drawing water into the bowel lumen through the osmotic effect of sulfate ions, inducing colonic evacuation. Additionally, magnesium ions enhance this effect by attracting water via osmotic pressure and stimulating the release of cholecystokinin, which promotes peristalsis.
2 sachets (each containing ascorbic acid 4.7g, macrogol 3350 52.5g, sodium ascorbate 5.9g, sodium sulfate 3.75g) dissolved in water to a total volume of 500mL, administered orally as a split-dose regimen: first dose (2 sachets in 500mL water) at 6-9 pm on the day before colonoscopy, followed by additional 500mL of clear fluids; second dose (2 sachets in 500mL water) on the morning of colonoscopy, completed at least 2 hours before the procedure, followed by additional 500mL of clear fluids.
24 tablets administered as 4 tablets every 15 minutes, total dose of 17.5 g sodium sulfate, 3.13 g magnesium sulfate, and 1.64 g potassium sulfate, orally, with water, the evening before colonoscopy.
None Documented
None Documented
Not applicable (non-absorbed agent); systemic absorption is minimal, so no terminal half-life is defined.
Terminal elimination half-life: 6-8 hours in adults with normal renal function; prolonged to 20-40 hours in end-stage renal disease.
Primarily fecal (90-95%) as unabsorbed drug; renal excretion is negligible (<1%).
Primarily renal excretion (65-75% unchanged) with minor biliary/fecal elimination (<10%). Total body clearance approximates renal blood flow.
Category C
Category C
Osmotic Laxative
Osmotic Laxative